Steven D. Singer, Partner, Wilmer Cutler Pickering Hale and Dorr
Genetics Advisory Council
Russell Hirsch, MD, PhD, Managing Director, Prospect Venture Partners.
Prior to establishing Prospect Venture Partners II, Russell was a member of the Health Care
Technology Group at Mayfield. He joined Mayfield in 1992, served as a Venture Partner from
1993 to 1994 and as a General Partner from 1995-2000. Russell played a key role in Mayfield's
investment activities in the biotechnology and medical device sectors. As an Associate, he
participated actively in the incubation of Millennium Pharmaceuticals and as a General Partner he
was responsible for the incubation of Intuitive Surgical Devices both of which are now publicly
traded. (NASDAQ: MLNM), (NASDAQ:ISRG).
Russell was at the University of California San Francisco from 1984-1992 where he was engaged
in biomedical research. His work, published in a variety of respected journals, focused on
important aspects of hepatitis B viral replication. His descriptions of the reverse transcription and
packaging functions of polymerase gene products merited publication in Nature. Russell serves
or has served on the Board of Directors of Intuitive Surgical (NASDAQ: ISRG), Sunesis,
Valentis (NASDAQ: VLTS), Opus Medical, Orquest (NASDAQ: JNJ), Infinity Pharmaceuticals,
Genpath, Hansen Medical and several other privately-held companies. Russell serves on the
Boards of the Bay Area Bioscience Center and Interplast. Russell holds an M.D. and Ph.D. in
Biochemistry from the University of California, San Francisco and a B.A. in Chemistry from the
University of Chicago.
Bill Helman, General Partners Greylock
Bill joined Greylock in 1984. He is a graduate of Dartmouth College and the Harvard Business
School. Bill represents Greylock on the boards of CentrePath, Incipient, iPhrase, netNumina,
OATSystems, OutlookSoft, Reveal, Upromise, and Vettro. Bill also led Greylock's investments
in Exact Sciences (EXAS), Tessera (merged with iXL), Ontogeny, Hyperion Software, Filene's
Basement, Pharmacopeia (PCOP), Millennium Pharmaceuticals (MLNM), Staples.com (acquired
by Staples), and Vertex Pharmaceuticals (VRTX).
John G. Freund, MD, Founding Partner Skyline Ventures
John has been involved in founding, financing, managing and advising healthcare companies
since 1982. He began his career at Morgan Stanley in New York, where he co-founded the
Healthcare Group in the Corporate Finance Department and was later the original healthcare
partner at Morgan Stanley Ventures. He then was an operating executive for six years as
Executive Vice President of Acuson Corporation (an NYSE-traded company that is now part of
Siemens), where he ran Marketing and led the cross-functional management of the company’s
product introductions. In 1995, he licensed the technology that served as the core of Intuitive
Surgical, Inc. (NASDAQ:ISRG), co-founded the company and raised its initial venture capital.
He then spent two years as the West Coast partner at the Private Equity group of Chancellor
Capital Management (now INVESCO), before founding Skyline in 1997. He has experience with
most of the major sectors of the healthcare investment market including medical devices,
information technology, small molecule chemistry and biochips, biotechnology and diagnostics.
He received a B.A. from Harvard College, an M.D. from Harvard Medical School, and an M.B.A.
from Harvard Business School, where he was a Baker Scholar and won the Loeb Fellowship in
Finance. He was the co-author of The Official MBA Handbook, which spent 16 weeks on the
New York Times bestseller list in 1982.
Stephen A. Sherwin, M.D., Chairman and Chief Executive Officer
Dr. Sherwin, chairman of the board and chief executive officer, joined Cell Genesys in March
1990. Dr. Sherwin has served as chief executive officer since our inception and, in March 1994,
was elected to the additional position of chairman of the board of directors. Dr. Sherwin also
served as president until July 2001, at which time Dr. Vallner was appointed president. From
1983 to 1990, Dr. Sherwin held various positions at Genentech, Inc., a biotechnology company,
most recently as vice president of clinical research. Prior to 1983, Dr. Sherwin was on the staff of
the National Cancer Institute. Dr. Sherwin currently serves as the chairman of the board for
Ceregene, Inc., a majority-owned subsidiary of Cell Genesys and a company that he co-founded
in 2001. He was also a co-founder of Abgenix, Inc., a former subsidiary of Cell Genesys. Dr.
Sherwin currently serves as member of the board of directors for Neurocrine Biosciences, Inc.
and Rigel Pharmaceuticals, Inc. and also serves as a board member of the Biotechnology Industry
Organization. He holds a B.A. in biology from Yale University and an M.D. from Harvard
Medical School and is board-certified in internal medicine and medical oncology
James N. Topper, M.D., Ph.D., Venture Partner, Frazier Healthcare
Dr. Topper works primarily on seed/early stage biotech investment opportunities. Prior to joining
Frazier Healthcare in August 2003, he served as head of the cardiovascular research and
development franchise at Millennium Pharmaceuticals and ran Millennium San Francisco
(formerly COR Therapeutics). Prior to the merger of COR and Millennium, Dr. Topper served as
the Vice President of Biology at COR, and was responsible for managing all of its research
activities. He served on the faculties of Stanford Medical School and Harvard Medical School
prior to joining COR, where he functioned as a clinician, instructor and basic investigator.
Dr. Topper received his M.D. and Ph.D. (in Biophysics) from Stanford University School of
Medicine in 1991 under the auspices of the Medical Scientist Training Program. He completed
his postgraduate training in Internal Medicine and Cardiovascular Disease at the Brigham and
Women's Hospital in Boston and is board certified in both disciplines. After completing a
research fellowship in the Vascular Research Division in the department of Pathology at the
Brigham and Women's hospital, he joined the faculty of Harvard Medical School from
1997-1998, and subsequently Stanford University as an Assistant Professor of Medicine
(Cardiovascular) in July 1998. He has authored over 50 publications, and was the recipient of a
Howard Hughes Scholars Award while on the faculty at Stanford University. He continues to
hold an appointment as a Clinical Assistant Professor of Medicine at Stanford University and as a
Cardiology Consultant to the Palo Alto Veterans Administration Hospital.
Dr. Topper currently serves as an observer on the boards of CoTherix, Inc., and Portola
Norman C. Selby, Chairman, Windhover Information, Inc.
Mr. Selby is currently the Chairman of Windhover Information, Inc., a publishing and
information company in the pharmaceutical, biotechnology and medical products industries. Prior
to that, Mr. Selby served as the president and chief executive officer of TransForm
Pharmaceuticals, Inc. Previously, he served as the head of Consumer Internet Business at
Citigroup/Citicorp. Also, Mr. Selby was head of the global pharmaceuticals practice at McKinsey
& Company, the international management consulting firm, and the interim chief operating
officer of the New York Blood Center. Currently, he is also on the board of Transform
Pharmaceuticals, Inc., Medsite, Inc. and the Memorial Sloan-Kettering Cancer Center. Mr. Selby
holds a bachelor's degree in architecture from Yale College, and he received his MBA from the
Harvard Graduate School of Business Administration.
A. Grant Heidrich, III, Partner Emeritus, Mayfield
Mr. Heidrich is a partner at Mayfield, a California-based venture capital firm focused on early-
stage technology companies. Previously, he served as vice president of Wood River Capital, a
New York City-based venture capital firm. Currently, Mr. Heidrich serves on the board of
directors at a number Grant has served as President of the Western Association of Venture
Capital and is a former board member of the National Venture Capital Association. He earned a
Bachelor's degree in human biology from Stanford University and an M.B.A. from Columbia
Robert Tepper, M.D., President, Research and Development, Millennium Pharmaceuticals
Dr. Tepper has served as chief scientific officer at Millennium since March 1999. He joined
Millennium in August 1994 as director of biology and became vice president, biology in January
1996. From 1990 to 1994, Dr. Tepper served as director of the laboratory of tumor biology at
Massachusetts General Hospital Cancer Center where he was the recipient of the Lucille P.
Markey Biomedical Scholar award. Dr. Tepper is also a founder and former member of the
scientific advisory board of Cell Genesys, Inc. He currently serves as a member of the National
Advisory Council for Human Genome Research. Dr. Tepper received his M.D. from Harvard
Medical School and completed his residency in medicine at Massachusetts General Hospital,
where he was chief resident. He continues to serve as an adjunct faculty member of Harvard
Medical School and the Massachusetts General Hospital and as a member of the Board of
Associates of the Whitehead Institute for Biomedical Research.
Jeff Elton,Principal, McKinsey & Company
Jeff Elton, Ph.D. is a principal in McKinsey & Company's Boston Office. Dr. Elton focuses on
technology-intensive industries, including biotechnology, pharmaceuticals, health and
bioinfomatics and medical devices. He is a leader of the Firm's Product Development and
Pharmaceutical and Medical Products Practices. Jeff is on the Board of Directors of the
Elizabeth Glaser Pediatric AIDS Foundation
Michael Schmertzler Managing Director of Aries Advisors, LLC,
Michael is a sub-advisor to Credit Suisse First Boston Equity Partners, LLC and its affiliates, and
the Chair of the Investment Committee of those funds. Mr. Schmertzler is an Adjunct Professor at
Yale University. Prior to Aries, Mr. Schmertzler was Co-Head of U.S. and Canadian Private
Equity at Credit Suisse First Boston. Prior to Credit Suisse First Boston, Mr. Schmertzler was the
President of the Morgan Stanley Leveraged Capital Funds and Morgan Stanley Leveraged Equity
Fund II, as well as a Managing Director in that firm’s mergers and acquisitions and corporate
finance departments. Mr. Schmertzler had previously been the Head of International Investment
Banking and International Institutional Sales and Trading at Shearson Lehman American Express
and a member of that firm’s Board of Directors. Prior to that, he was Chief Financial Officer, a
Managing Director, and an investment banker at Lehman Brothers Kuhn Loeb Incorporated. Mr.
Schmertzler currently serves on the boards of Idenix Pharmaceuticals, PTC Therapeutics,
Segway, Triad Therapeutics and Zyomyx; he is a designated board observer at Sunesis
Pharmaceuticals and is a Trustee of the National Outdoor Leadership School. Mr. Schmertzler
received his B.A. from Yale College in Molecular Biophysics and Biochemistry, History, and
City Planning. He attended the Woodrow Wilson School at Princeton University and received an
M.B.A. from the Harvard Business School
Marcia A. Kean, Chief Executive Officer, Feinstein Kean Healthcare
Marcia Kean has close to 30 years of health care industry experience, including senior positions
with pharmaceutical, biotechnology and medical service firms, non-profit research organizations,
and consulting firms. Marcia has been a prominent author and speaker on key communications
and valuation issues facing senior management. Prior to her recent appointment as Chief
Executive Officer of Feinstein Kean Healthcare, she was SVP-Commercialization at Ardais
Corporation, a privately held clinical genomics firm. Mrs. Kean served as founder and Managing
Director of the Corporate Communications practice at Feinstein Kean Healthcare. In that role, she
led a full-service U.S. and international corporate communications practice, with specialization in
the definition and repositioning of corporate identities; planning and fulfillment of valuation
potential; investor relations and media strategy and execution; and management of sensitive or
challenging corporate issues. From 1982 to 1990, Mrs. Kean served simultaneously as vice
president, corporate communications of Damon Corporation (NYSE) and of its subsidiary,
Damon Biotech (Nasdaq). Mrs. Kean holds an M.B.A. in finance from New York University and
a B.A. from the University of California at Berkeley.
Steven D. Singer, Partner, Wilmer Cutler Pickering Hale and Dorr
Mr. Singer is Co-Chair, Life Sciences Group; Vice Chair, Corporate Department and practices
general corporate law, and primarily represents biotechnology and biomedical companies. Mr.
Singer has extensive experience in corporate partnering and joint venture and licensing
agreements. He has worked on a wide range of corporate transactions, including public and
private securities offerings, mergers and acquisitions, research and development agreements, joint
ventures, license agreements, and other major and minor corporate work. Mr. Singer is a
member of the American Bar Association, the Massachusetts Biotechnology Council and the
Biotechnology Industry Organization. Mr. Singer received a J.D. degree, magna cum laude, from
Harvard Law School, where he was a member of the Harvard Law Review. He graduated summa
cum laude from Tufts University